Collegium Pharmaceutical, Inc. COLL
24.47 USD -0.24 (-0.97%)
At closeNov 10, 2026, 4:05 PM EST
24.47 0.00 0.00%
After hours · Nov 10, 4:05 PM ET
24.14 Day range 24.95
21.43 52-week range 50.79
- YTD
- -47.15%
- 1 year
- -43.79%
News
zacks.com Wall Street Analysts Believe Collegium Pharmaceutical (COLL) Could Rally 81.63%: Here's is How to Trade The mean of analysts' price targets for Collegium Pharmaceutical (COLL) points to an 81.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong…
seekingalpha.com Collegium Pharmaceutical, Inc. (COLL) Q3 2026 Earnings Call Transcript Collegium Pharmaceutical, Inc. ( COLL ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Ian Karp - Head of Investor Relations Vikram Karnani - CEO, President & Director…
benzinga.com Piper Sandler Maintains Neutral on Collegium Pharmaceutical, Lowers Price Target to $28 Piper Sandler analyst David Amsellem maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $43 to $28.
benzinga.com Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $44 Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $46 to $44.
zacks.com Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.96 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $2.25 per share a year ago.
benzinga.com Collegium Pharmaceutical Q3 2026 Earnings Call Transcript Collegium Pharmaceutical (NASDAQ:COLL) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Collegium Pharmaceutical Affirms FY2026 Sales Guidance of $825.000M-$855.000M vs $835.780M Est Collegium Pharmaceutical (NASDAQ:COLL) affirms FY2026 sales outlook from $825.000 million-$855.000 million to $825.000 million-$855.000 million vs $835.780 million estimate.- benzinga.com Collegium Pharmaceutical Q3 Adj. EPS $1.96 Beats $1.86 Estimate, Sales $216.339M Miss $217.276M Estimate Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $1.96 per share which beat the analyst consensus estimate of $1.86 by 5.38 percent. This is a 12.89 percent decrease over…
globenewswire.com Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance – Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS…
zacks.com COLL or SDZNY: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Collegium Pharmaceutical (COLL) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks…
benzinga.com Collegium Pharmaceutical And Grünenthal Enter Settlement Agreement On Oct 15, 2026; Terminates Grünenthal License And Consent Agreement For Territory Effective Oct 15, 2026; Co. To Pay Grünenthal $17M In Settlement As previously disclosed, Collegium Pharmaceutical, Inc. (the "Company") is party to a License Agreement (U.S.), dated as of January 13, 2015, with Grünenthal GmbH ("Grünenthal") (as amended, the
benzinga.com Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call Transcript Collegium Pharmaceutical (NASDAQ:COLL) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs.…
benzinga.com Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50 Oppenheimer analyst Les Sulewski initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $50.
benzinga.com Truist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49 Truist Securities analyst Alexander Xenakis maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $58 to $49.- benzinga.com Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45 Leerink Partners analyst Daniel Clark initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $45.
benzinga.com Top 3 Health Care Stocks Which Could Rescue Your Portfolio In Q3 Healthcare stocks UTHR, COLL and AHG show oversold RSI levels near or below 30, potentially offering undervalued buying opportunities.
benzinga.com Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48 Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.
benzinga.com Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43 Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $45 to $43.- benzinga.com Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46 Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $46.
- benzinga.com Collegium Pharmaceutical Lowers FY2026 Sales Guidance from $865.000M-$895.000M to $825.000M-$855.000M vs $872.278M Est Collegium Pharmaceutical (NASDAQ:COLL) lowers FY2026 sales outlook from $865.000 million-$895.000 million to $825.000 million-$855.000 million vs $872.278 million estimate.
benzinga.com Collegium Pharmaceutical Affirms FY2026 Sales Guidance of $805.000M-$825.000M vs $825.757M Est Collegium Pharmaceutical (NASDAQ:COLL) affirms FY2026 sales outlook from $805.000 million-$825.000 million to $805.000 million-$825.000 million vs $825.757 million estimate.- benzinga.com Collegium Pharmaceutical Q1 Adj. EPS $1.76 Beats $1.59 Estimate, Sales $193.520M Beat $185.984M Estimate Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $1.76 per share which beat the analyst consensus estimate of $1.59 by 10.69 percent. This is a 18.12 percent increase over…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Collegium Pharmaceutical, Maintains $60 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and maintains $60 price target.
benzinga.com Collegium To Acquire AZSTARYS For $650M In Cash With Potential For Additional Milestone Payments Up To $135M Depending On Future Commercial And Regulatory Milestones – Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio –– Enables Greater Impact Across ADHD Patient Communities –– AZSTARYS…
benzinga.com Deep Dive Into Collegium Pharmaceutical Stock: Analyst Perspectives (5 Ratings) - benzinga.com Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $54 Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $54.
- benzinga.com Collegium Pharmaceutical Sees FY2026 Sales $805.000M-$825.000M vs $808.877M Est Collegium Pharmaceutical (NASDAQ:COLL) sees FY2026 sales of $805.000 million-$825.000 million vs $808.877 million analyst estimate.
benzinga.com Insights into Collegium Pharmaceutical Q4 Earnings - benzinga.com Collegium Pharmaceutical Q4 Adj. EPS $2.04 Misses $2.33 Estimate, Sales $205.449M Miss $206.362M Estimate Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $2.04 per share which missed the analyst consensus estimate of $2.33 by 12.37 percent. This is a 15.25 percent increase over…
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com Earnings Scheduled For May 8, 2025
- benzinga.com Earnings Scheduled For February 27, 2025
- benzinga.com Earnings Scheduled For February 22, 2024 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.
- benzinga.com Earnings Scheduled For November 7, 2023 Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
- benzinga.com Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session.
- benzinga.com Earnings Scheduled For August 3, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
- benzinga.com Earnings Scheduled For May 4, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
- benzinga.com Earnings Scheduled For February 23, 2023 Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
- benzinga.com Earnings Scheduled For November 3, 2022 Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
- benzinga.com Earnings Scheduled For August 4, 2022 Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 807 companies reached new 52-week lows.
- benzinga.com Earnings Scheduled For May 10, 2022 Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 435 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 213 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.
- benzinga.com Earnings Scheduled For November 4, 2021 Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.